Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Idenix Pharma Skids After Hepatitis Drug Delay

By Pharmaceutical Processing | June 24, 2013

NEW YORK (AP) — Shares of Idenix Pharmaceuticals Inc. tumbled Friday after the Food and Drug Administration delayed human testing of the company’s hepatitis C drug IDX20963.

THE SPARK: After the markets closed on Thursday, Idenix said the FDA wants more safety data on IDX20963 before it will allow the company to begin clinical trials. The company did not say how long it might take to satisfy the FDA’s concerns.

THE BIG PICTURE: The Cambridge, Mass., company does not have any approved products. Idenix is running mid-stage clinical trials of another hepatitis C drug, IDX719, and is running preclinical trials of other potential drugs.

Hepatitis C is a chronic infection that can cause liver damage, cirrhosis, liver failure, or cancer. The FDA approved the two new drugs for the disease in 2011, but a slew of companies are researching newer treatments that could have higher cure rates and fewer side effects. The market for the disease is also expected to grow as the U.S. population ages and more cases are diagnosed.

THE ANALYSIS: JPMorgan analyst Geoff Meacham downgraded Idenix shares to “Neutral” from “Overweight,” and cut his price target to $5 per share from $13. He said the delays could fall further behind Gilead Sciences Inc. and other competitors because of the delay. He said the main problem isn’t just the delay for IDX20963 itself: the company was planning to test a combination of that drug and IDX719. It can’t do that until the FDA’s safety concerns are addressed.

“Idenix will need its wholly owned combination of IDX-719 and IDX20963 to be competitive,” he said.

SHARE ACTION: Shares of Idenix dropped $1.63, or 31.8 percent, to $3.50 in afternoon trading. The stock had advanced 48 percent since May 1.

 

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE